Protagonist Therapeutics, Inc
PTGXNasdaq
$140.91
↑ +6.7%Jul 17 close · end-of-day
Price
1Y↑ +148.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.9B
Enterprise Value
$9.4B
P/E
—
P/S
134.1
P/B
15.2
EV/EBITDA
—
PEG
—
FCF Yield
-1.2%
Dividend Yield
—
Revenue (TTM)
$74.1M
Net Income (TTM)
-$114.7M
Free Cash Flow (TTM)
-$117.9M
Gross Margin
—
Operating Margin
-192.4%
Net Margin
-154.9%
ROE
-17.5%
ROIC
-104.5%
Debt / Equity
—
Net Cash
$547.8M
Return 1Y
+149.7%
Company profile
Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.
- CEO
- Dinesh V. Patel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Headquarters
- California
- Website
- protagonist-inc.com
Management & directors
- Patel Dinesh V Ph DPresident and CEO
- Ali AsifChief Financial Officer
- Molina Arturo MdChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
PTGX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$56.4M↑ +99.0%
Diluted EPS$0.05↓ -126.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$64.5M | -$125.8M | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| Net income | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| Diluted EPS | -$1.92 | -$2.71 | -$2.60 | -$1.39 | $4.23 | -$2.05 |
| Operating cash flow | -$72.5M | -$107.9M | -$108.1M | -$70.2M | $184.2M | $57.7M |
| Free cash flow | -$73.0M | -$109.0M | -$108.9M | -$70.8M | $182.8M | $56.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -225.4% | -460.0% | -494.2% | -156.1% | 58.2% | -343.6% |
| Net margin | -231.1% | -458.9% | -479.3% | -131.6% | 63.3% | -282.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $4.7M | $170.6M | $28.3M | $5.5M | $4.7M | $7.4M | $56.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$38.8M | -$41.5M | $126.8M | -$19.3M | -$42.0M | -$46.4M | -$50.4M | -$3.6M |
| Net income | -$30.6M | -$33.2M | $131.7M | -$11.7M | -$34.8M | -$39.3M | -$44.4M | $3.8M |
| Diluted EPS | -$0.50 | -$0.54 | $2.01 | -$0.19 | -$0.55 | -$0.62 | -$0.69 | $0.05 |
| Operating cash flow | $268.6M | -$27.9M | -$29.2M | $125.4M | -$28.8M | -$1.9M | -$37.0M | -$48.9M |
| Free cash flow | $268.6M | -$28.6M | -$29.5M | $124.8M | -$29.6M | -$2.0M | -$37.1M | -$49.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -931.0% | -886.7% | 74.3% | -68.2% | -758.0% | -985.2% | -677.1% | -6.5% |
| Net margin | -734.7% | -710.4% | 77.2% | -41.2% | -627.0% | -834.9% | -596.8% | 6.7% |
Company news
Jul 13, 2026
Jul 9, 2026
Jul 8, 2026
- 12d agoProtagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?finance.yahoo.com
- 12d agoProtagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?finance.yahoo.com
- 12d agoStrength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-23 | Waddill William D. | Sale | 9,000 | $117.94 | $1.1M | filing |
| 2026-06-23 | Waddill William D. | Option exercise | 9,000 | $16.54 | $148,860.00 | filing |
| 2026-06-10 | Waddill William D. | Sale | 9,000 | $107.68 | $969,120.00 | filing |
| 2026-06-10 | Waddill William D. | Option exercise | 6,000 | $16.54 | $99,240.00 | filing |
| 2026-06-10 | Waddill William D. | Option exercise | 3,000 | $11.80 | $35,400.00 | filing |
| 2026-05-29 | Waddill William D. | Sale | 9,000 | $99.64 | $896,760.00 | filing |
| 2026-05-29 | Waddill William D. | Option exercise | 9,000 | $11.80 | $106,200.00 | filing |
| 2026-05-12 | PATEL DINESH V PH D· President and CEO | Sale | 75,000 | $100.12 | $7.5M | filing |
| 2026-05-12 | PATEL DINESH V PH D· President and CEO | Sale | 75,000 | $100.12 | $7.5M | filing |
| 2026-05-12 | PATEL DINESH V PH D· President and CEO | Option exercise | 75,000 | $21.58 | $1.6M | filing |
| 2026-05-12 | PATEL DINESH V PH D· President and CEO | Option exercise | 75,000 | $21.58 | $1.6M | filing |
| 2026-05-08 | Giraudo Bryan | Sale | 6,000 | $100.00 | $600,000.00 | filing |
| 2026-05-08 | Giraudo Bryan | Sale | 5,130 | $100.00 | $513,000.00 | filing |
| 2026-05-07 | Giraudo Bryan | Sale | 36,000 | $100.14 | $3.6M | filing |
| 2026-05-07 | Giraudo Bryan | Sale | 12,000 | $100.07 | $1.2M | filing |
| 2026-05-07 | Giraudo Bryan | Option exercise | 24,000 | $6.45 | $154,800.00 | filing |
| 2026-05-07 | Giraudo Bryan | Option exercise | 12,000 | $6.98 | $83,760.00 | filing |
| 2026-04-23 | PATEL DINESH V PH D· President and CEO | Gift | 1,460 | $0.00 | $0.00 | filing |
| 2026-04-20 | Ali Asif· Chief Financial Officer | Sale | 1,750 | $105.47 | $184,572.50 | filing |
| 2026-03-26 | Ali Asif· Chief Financial Officer | Sale | 24,765 | $104.24 | $2.6M | filing |
| 2026-03-26 | SELICK HAROLD E | Sale | 24,000 | $105.00 | $2.5M | filing |
| 2026-03-26 | MOLINA ARTURO MD· Chief Medical Officer | Sale | 15,000 | $104.79 | $1.6M | filing |
| 2026-03-26 | Ali Asif· Chief Financial Officer | Option exercise | 19,500 | $19.19 | $374,205.00 | filing |
| 2026-03-26 | SELICK HAROLD E | Option exercise | 24,000 | $12.88 | $309,120.00 | filing |
| 2026-03-26 | MOLINA ARTURO MD· Chief Medical Officer | Option exercise | 15,000 | $8.04 | $120,600.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.